The successful joint launch ceremony for the human clinical trial of the ABROBO PANVIS pan-vascular interventional robot took place on October 20 at the Pan-Vascular Interventional Robot Symposium during the Oriental Conference of Interventional Neurovascology 2023 (OCIN 2023).

Mr. Lu Xiaohua, Deputy General Manager of Shenzhen Abrobo Co., Ltd., chaired the trial launch ceremony. The event was attended by esteemed guests, including Professor Vitor Mendes Pereira, Director of Neurovascular Intervention at St. Michael's Hospital, University of Toronto, Canada; Professor Liu Jianmin from the First Affiliated Hospital of Naval Medical University; Professor Fu Weiguo from Zhongshan Hospital Affiliated to Fudan University; Professor Pei Zhiqiang, representative of Academician Ge Junbo’s team at Zhongshan Hospital Affiliated to Fudan University; Professor Guo Shuxiang, chairman and founder of Shenzhen Abrobo Co., Ltd., and foreign academician of the Japanese Academy of Engineering; Dr. Guo Jian, General Manager of Abrobo; along with two deputy general managers, Mr. Cao Zhi and Dr. Ren Wenyong.

Professor Liu Jianmin and Dr. Ren Wenyong presented keynote speeches during the ceremony.

Professor Liu Jianmin presented the outcomes of human clinical trials conducted using Roboangio, Abrobo's pioneering neurointerventional robot. He highlighted how Abrobo's control system in vascular interventional surgery assists physicians in precisely navigating catheters and guidewires for completing cerebral angiography. The clinical success rate matched, if not exceeded, that of traditional manual cerebral vascular interventional angiography. Before its clinical application, extensive simulations, animal experiments, and training sessions were conducted. The enrollment of a significant number of patients—63 cases in the experimental group and 65 cases in the control group—spanning the First Affiliated Hospital of Naval Medical University, Wenzhou Central Hospital, Zhangzhou Hospital of Fujian Province, and Zhuhai People's Hospital, was achieved within a mere four months.

After intraoperative image assessment, an independent third-party core laboratory evaluated the primary efficacy endpoint—clinical success rate—for both the experimental and control groups, encompassing patients who underwent surgeries. The findings revealed no discernible disparity between angiography conducted by a robot versus that performed by a clinician. Moreover, secondary effectiveness indicators—including the success rate of super-selection technology, average time for targeted vessel super-selection, surgical operation duration, and DSA fluoroscopy time—showed no significant differentiation between the test and control groups. These results affirm the reliability and consistent clinical performance of the test product

The excitement mounts as the experimental group achieves a remarkable 100% success rate with the super-selective technology. Utilizing the experimental equipment, surgeons effortlessly execute high-precision super-selective intubation procedures. While the installation of trial equipment pre-operatively might pose challenges, its clinical performance remains consistent and reliable. Notably, despite the time-consuming pre-operative installation that extends the overall operation duration, the effective operation time aligns with that of traditional manual surgery. This extension doesn't compromise subjects' safety or clinical efficacy. Impressively, the primary operator's exposure to iatrogenic ionizing radiation significantly decreases in the experimental group compared to the control group, highlighting the test product's efficacy in minimizing radiation absorption. Overall, the test product excels across various performance metrics, demonstrating exceptional capability.

No noticeable distinction emerged between the experimental and control groups concerning endpoint security. Notably, the entire experiment proceeded without any adverse events related to the research device or any observed device flaws. The test instrument meets the necessary criteria for clinical utilization and boasts a high level of safety.

Dr. Ren Wenyong introduced Abrobo's initial neurointerventional robot, Roboangio, alongside the forthcoming pan-vascular interventional robot, PANVIS Star, detailing their unique features and advantages. He highlighted PANVIS Star's merits, emphasizing zero radiation exposure for surgeons, swift instrument exchange during surgeries, and exceptional adaptability. Notably, its remote system fosters enhanced medical resource accessibility by linking esteemed hospitals with peripheral community healthcare centers. Moreover, the revolutionary "fingertip catheter" operating system, COF (Catheter-On-Finger), significantly reduces the learning curve for doctors while elevating surgical precision and safety standards.